文献速递头颈外科

社区层面劣势与头颈癌辅助治疗延迟

Neighborhood-Level Disadvantage and Delayed Adjuvant Therapy in Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项回顾性队列研究纳入2018至2020年4家美国学术医疗中心681例接受根治性手术及术后放疗的头颈鳞状细胞癌患者,评估社区层面劣势(ADI评分)与术后放疗延迟(>6周)的关联。ADI评分每增加25分,延迟放疗的校正比值比为1.32(95%CI 1.07-1.63);ADI评分越高,开始放疗时间越长。

要点

  • 681例头颈鳞癌患者术后放疗延迟率为60.8%(414/681),开始放疗中位时间46天。
  • ADI评分每增加25分,术后放疗延迟的校正比值比为1.32(95%CI 1.07-1.63)。
  • ADI评分第2、3、4四分位较第1四分位,开始放疗的风险比分别为0.71、0.59、0.54。

核心结论

  • 社区层面劣势增加与术后放疗延迟可能性更高及开始放疗时间更长独立相关,呈剂量依赖方式。
  • 作者认为亟需制定多层次策略以改善及时、符合指南的术后放疗的公平实施。

研究设计与样本

  • 回顾性队列研究,纳入2018至2020年美国4家学术医疗中心681例接受根治性手术及术后放疗的成人头颈鳞状细胞癌患者。
  • 数据分析时间为2023年6月21日至2024年3月5日。

主要发现

  • 681例患者平均(SD)年龄61.5(11.2)岁,男性487例(71.5%),女性194例(29.5%)。
  • 术后放疗延迟率为60.8%(414/681),开始放疗中位(IQR)时间为46(40-56)天。
  • ADI评分中位(IQR)为62.0(44.0-83.0)。
  • ADI评分每增加25分,术后放疗延迟的校正比值比为1.32(95%CI 1.07-1.63),模型校正了机构、年龄、种族和民族、保险、合并症、肿瘤亚部位、分期、术后并发症、照护碎片化、旅行距离和农村性。
  • 与ADI第1四分位相比,第2、3、4四分位开始放疗的风险比分别为0.71(95%CI 0.53-0.96)、0.59(95%CI 0.44-0.77)、0.54(95%CI 0.41-0.72)。

关键数值与推荐

  • 国家综合癌症网络指南和癌症委员会推荐头颈鳞状细胞癌术后6周内开始术后放疗。
  • 主要结局为术后放疗延迟,即手术后超过6周开始放疗。
  • ADI评分基于人口普查街区层面计算,以全国百分位数(0-100)报告,评分越高表示劣势越大。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with head and neck squamous cell carcinoma (HNSCC), initiation of postoperative radiation therapy (PORT) within 6 weeks of surgery is recommended by the National Comprehensive Cancer Network Guidelines and the Commission on Cancer. Although individual-level measures of socioeconomic status are associated with receipt of timely, guideline-adherent PORT, the role of neighborhood-level disadvantage has not been examined. OBJECTIVE: To characterize the association of neighborhood-level disadvantage with delays in receiving PORT. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 681 adult patients with HNSCC undergoing curative-intent surgery and PORT from 2018 to 2020 at 4 US academic medical centers. The data were analyzed between June 21, 2023, and March 5, 2024. MAIN OUTCOME MEASURES AND MEASURES: The primary outcome was delay in initiating guideline-adherent PORT (ie, >6 weeks after surgery). Time-to-PORT (TTP) was a secondary outcome. Census block-level Area Deprivation Index (ADI) scores were calculated and reported as national percentiles (0-100); higher scores indicate greater deprivation. The association of ADI scores with PORT delay was assessed using multivariable logistic regression adjusted for demographic, clinical, and institutional characteristics. PORT initiation across ADI score population quartiles was evaluated with cumulative incidence plots and Cox models. RESULTS: Among 681 patients with HNSCC undergoing surgery and PORT (mean [SD] age, 61.5 [11.2] years; 487 [71.5%] men, 194 [29.5%] women) the PORT delay rate was 60.8% (414/681) and median (IQR) TTP was 46 (40-56) days. The median (IQR) ADI score was 62.0 (44.0-83.0). Each 25-point increase in ADI score was associated with a corresponding 32% increase in the adjusted odds ratio (aOR) of PORT delay (aOR, 1.32; 95% CI, 1.07-1.63) on multivariable regression adjusted for institution, age, race and ethnicity, insurance, comorbidity, cancer subsite, stage, postoperative complications, care fragmentation, travel distance, and rurality. Increasing ADI score population quartiles were associated with increasing TTP (hazard ratio of PORT initiation, 0.71; 95% CI, 0.53-0.96; 0.59; 95% CI, 0.44-0.77; and 0.54; 95% CI, 0.41-0.72; for ADI quartiles 2, 3, and 4 vs ADI quartile 1, respectively). CONCLUSIONS AND RELEVANCE: Increasing neighborhood-level disadvantage was independently associated with a greater likelihood of PORT delay and longer TTP in a dose-dependent manner. These findings indicate a critical need for the development of multilevel strategies to improve the equitable delivery of timely, guideline-adherent PORT.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Graboyes EM, Cagle JL, Ramadan S, et al. Neighborhood-Level Disadvantage and Delayed Adjuvant Therapy in Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38662392. doi:10.1001/jamaoto.2024.0424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。